ATLASMadrigal Pharmaceuticals (MDGL) earnings date: Nov 3, 2026
Madrigal Pharmaceuticals (MDGL) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 3, 2026, before the open. Analysts expect EPS of -$1.09.
Source: company filings and exchange data · Updated Nov 2, 2026
Madrigal Pharmaceuticals reports on Nov 3, 2026. One email the day before, with ATLAS’s read on Madrigal Pharmaceuticals. You can switch it off at any time.
Alert me before MDGL reportsFree to start. Creating an account takes under a minute.
MDGL earnings at a glance
| Next report (confirmed) | Tue, Nov 3, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.09 |
| Last report | Jul 28, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +6.7% |
| Average move around a report | ±5.5% (last 4) |
| Sector | Healthcare · Biotechnology |
Madrigal Pharmaceuticals earnings history: last 4 reports
Madrigal Pharmaceuticals last reported on Jul 28, 2026: EPS of $0.89 against an estimate of $0.87 (+2.3% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Jul 28, 2026 | $0.87 | $0.89 | +2.3% | Beat | -0.8% |
| May 6, 2026 | -$4.14 | -$1.38 | +66.7% | Beat | +6.5% |
| Mar 4, 2026 | $0.06 | $0.15 | +150.0% | Beat | +3.2% |
| Feb 19, 2026 | -$0.88 | -$2.57 | -192.0% | Miss | -11.5% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
ATLAS view on MDGL before the report
| Last price | $430.36 (-0.3%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 50% |
| Likely 1-month range (50%) | $402.13 – $460.08 |
| Normal 1-day range (±1σ) | ±2.3% |
These figures come from the same calibrated model and valuation as the Madrigal Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Get the full ATLAS analysis for MDGL
See the fair value, the probability range and the earnings history of Madrigal Pharmaceuticals on its ATLAS page.
Madrigal Pharmaceuticals (MDGL) stock analysisPlans from €3.99 a month.
Madrigal Pharmaceuticals earnings: frequently asked questions
When does Madrigal Pharmaceuticals (MDGL) report earnings?
Madrigal Pharmaceuticals is scheduled to report on Tuesday, November 3, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MDGL?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.09 per share (USD). Estimates can change before the report.
How often does MDGL beat earnings estimates?
Of its last 4 reports with a recorded result, Madrigal Pharmaceuticals beat the EPS estimate 3 times; the average surprise was +6.7%. Past results do not predict the next one.
How much does MDGL move around earnings?
Over its last 4 reports the stock moved an average of 5.5% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did Madrigal Pharmaceuticals beat earnings estimates last quarter?
Madrigal Pharmaceuticals last reported on Jul 28, 2026: EPS of $0.89 against an estimate of $0.87 (+2.3% surprise), a beat.
How much does MDGL usually move in a day?
On a normal trading day the ATLAS model puts MDGL’s one-day range at about ±2.3%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 3, 2026
Educational information, not investment advice. Disclaimer